Pfizer’s experimental COVID-19 antiviral treatment is able to reduce the risk of hospitalization or death from the CCP (Chinese Communist Party) virus by 89 percent when taken shortly after initial symptoms, the company announced on Tuesday in its full analysis of data from the trial.
The U.S.-based pharmaceutical company’s final testing results on the drug, known as PAXLOVID, remain consistent with an interim analysis it published last month.
